Advertisement

News & Opinion

Covering the life sciences inside and out

Most Recent

Update on the global AIDS epidemic (Asia)

By | June 30, 2000

Small signs of hope amidst increasing gloom. That's the world AIDS situation according to UNAIDS.

0 Comments

Update on the global AIDS epidemic (Latin America)

By | June 30, 2000

Small signs of hope amidst increasing gloom. That's the world AIDS situation according to UNAIDS.

0 Comments

Update on the global AIDS epidemic (The newly independent states)

By | June 30, 2000

Small signs of hope amidst increasing gloom. That's the world AIDS situation according to UNAIDS.

0 Comments

Warfarin and cancer

June 30, 2000

New York, June 30, 2000 (Praxis Press) - The incidence of cancer increases after the diagnosis of venous thromboembolism, which is usually treated with vitamin K antagonists such as warfarin. Few randomized trials have examined the relation between the development of metastases and the clotting mechanism. During a prospective, randomized study that lasted eight years, Schulman and Lindmarker have compared the effects on the incidence of cancer of a six-week and a six-month warfarin treatment giv

0 Comments

Gene targeting in sheep raises new hopes and fears

By | June 29, 2000

PPL Therapeutics Ltd of Roslin, Edinburgh, showed today how they succeeded a year ago (the delay was to secure a patent) in targeting a gene to a chosen location in embryonic sheep fibroblasts. Then they transferred the nucleus to stem cells and created whole transformed, gene-targeted sheep (Nature paper 1 and paper 2).We have succeeded in cloning sheep, goats, cows, pigs and mice, and now we have gene targeting in sheep. But it is proving difficult to clone whole animals efficiently, as the sc

0 Comments

Amiodarone guidelines

June 28, 2000

New York, June 28, 2000 (Praxis Press) Clinical trials demonstrate the efficacy, broad anti-arrhythmic and anti-fibrillatory action, and complex array of adverse effects of amiodarone. The absence of general recommendations for proper patient management likely leads to both overuse and underuse of this drug. Practical guidelines from the North American Society of Pacing and Electrophysiology provide the physician with a consensus approach to the prescription of amiodarone (see paper). Based on t

0 Comments

New York, June 28, 2000 (Praxis Press) Within a few weeks of initiating antihypertensive therapy, physicians often escalate the dosage because of insufficient result, or discontinue the medication because of its perceived adverse side effects. Some studies suggest that hypertension is not an asymptomatic condition and may be responsible for some adverse effects. In a parallel-group clinical trial with randomized participants starting with a 20-mg daily dosage of the angiotensin-converting enzy

0 Comments

Chest pain and mortality

June 28, 2000

NEW YORK, June 28 (Praxis Press) Although chest pain is widely considered a key symptom of myocardial infarction (MI), not all patients with MI present with chest pain. To determine the frequency with which patients with MI present without chest pain and to examine their subsequent management and outcome, Canto and colleagues performed an observational study of patients with MI (see paper). They examined a total of 434,877 patients and evaluated mortality among MI patients without chest pain and

0 Comments

New York, June 28, 2000 (Praxis Press) Interstitial lung disease is a major cause of death in patients with systemic sclerosis (scleroderma). Studies have not precisely evaluated the association between alveolitis and lung fibrosis, and the subsequent deterioration of pulmonary function. A recent retrospective cohort study compared the outcomes of three patient groups with scleroderma lung disease: patients without alveolitis, and alveolitis patients with and without cyclophosphamide treatment a

0 Comments

GERD treatment

June 28, 2000

New York, June 28, 2000 (Praxis Press) Clinical studies showing the superiority of proton pump inhibitors over histamine-2 receptor antagonists (H2RAs) in the treatment of severe gastroesophageal reflux disease (GERD) have not been extended to patients with the milder nonerosive form of the condition, which accounts for the majority of GERD cases. According to a new study, the proton pump inhibitor lansoprazole is more effective than the H2RA ranitidine or a placebo for milder (nonerosive) form

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
EMD Millipore
EMD Millipore

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
NuAire Inc.
NuAire Inc.
Advertisement
The Scientist
The Scientist
Life Technologies